Naturally-occurring compounds have been, and continue to be, an important source of new leads and of commercially successful products for various industrial sectors, notably pharmaceuticals and agrochemicals. The conference, Functional Molecules from Natural Sources, held at Magdalen College, Oxford, in July 2009 set out to highlight current trends, challenges and successes in the exploitation of natural products from microbial, plant and marine sources. Based on the proceedings of this conference, the main themes of this book are modern and emerging perspectives on natural product utilization and improved strategies for natural products exploitation. It provides case studies on important natural product leads (functional molecules) and their enhancement. These take account of new medical applications, and advances in the understanding and manipulation of natural product biosynthesis at the genetic level. Highlights include an authoritative review of the entire field of natural anticancer agents, (with an emphasis on those currently in clinical development); an account of the optimisation of the pleuromutilin antibiotic template for human use, and a comprehensive description of the research programme that resulted in the discovery of platensimycin. Aricles on biosynthesis include studies of the antibiotics of Streptomyces coelicolor A3(2), the anthrax siderophore petrobactin, and the modification of oxidation and glycosylation events in the biosynthesis of mithramycins. Written by leading industrial experts from each sector, the book offers a unique blend of industrial and academic perspectives. It summarizes new approaches to optimising the exploitation of naturally occurring compounds within the pharmaceutical, nutraceutical and agrochemicals industries. New approaches to optimising the exploitation of naturally occurring compounds (including the genetics of natural product biosynthesis), novel screening technologies and recent advances in characterization methods are also covered.
Wrigley / Thomas / Nicholson
Functional Molecules from Natural Sources jetzt bestellen!
Weitere Infos & Material
Antitumour Agents from Nature; From Natural Products to Medicinal Chemistry; New Approaches for Drug Discovery with Natural Products; Biosynthesis and Biosynthetic Engineering of Nonribosomal Lipopeptides; Why Natural Product Discovery Won't Meet the Requirements of Market-Driven Economics; Marine Natural Products; From the Seabed to the Hospital Bed; Development of Lantibiotics for Treatment of Nosocomial Infections; Imino Sugars: A Major New Group of Therapeutic Agents; Well, Naturally; Modifying Oxidation and Glycosylation Events in the Biosynthesis of Natural Product Anticancer Drugs û Challenges for Combinatorial Biosynthesis; Pleuromutilins: Antibiotic Optimisation for Human Therapeutic Use; Acetogenic Anthraquinones and Alkaloids - Online Structural Elucidation, Biosynthesis, Bioactivities and Total Synthesis; Finding New Antibacterials: Opening a Window on the Black Box of Natural Product Discovery; Potential Plant Natural Products for Management of Neglected Diseases; Chemical Diversity by Other Means: The Biosynthesis of Polyketide Drugs; Structural, Synthetic and Biosynthetic Studies on an 'Acyl Transferase-Less. Polyketide Antibiotic, Mupirocin; Switching on Defence Genes with Plant Secondary Metabolites; Natural Products as Leads for New and Innovative Crop Protection Chemicals
Stephen K. Wrigley has worked in the field of industrial natural products drug discovery and development for twenty five years. He is currently Chief Technical Officer at Hypha Discovery Ltd., where his scientific interests are focused on the identification and evaluation of novel basidiomycete metabolites with anticancer and antimicrobial activities. Prior to joining Hypha, he led efforts to characterize and develop new lipopeptide antibiotics at RecombinoGen Ltd. Steve was formerly Senior Director of Research for Cubist Pharmaceuticals (UK) Ltd., where he led a team engaged in antibiotic screening and participated in programmes to generate improved lipopeptides through chemical and genetic modification. He had previously held research management and scientific positions involving microbial product discovery at TerraGen Discovery, Inc., Xenova Ltd. and Glaxo Group Research Ltd. Steve obtained BSc and PhD degrees, both in chemistry, from Imperial College, University of London, in 1982 and 1985, respectively.
